Table 3 Meta-analysis for secondary outcomes
Outcome | Trials (n) | Patients (n) | Type | RR (95 % CI)a | P-value | Heterogeneity | |
|---|---|---|---|---|---|---|---|
I2 % | P-value | ||||||
New-onset diabetes mellitus | 10 | 3550 | Fixed | 1.32 (1.07-1.62) | 0.008 | 4 | 0.40 |
Urinary tract infection | 7 | 2926 | Fixed | 1.00 (0.87-1.15) | 0.96 | 15 | 0.32 |
CMV infection | 11 | 4622 | Random | 0.40 (0.27-0.59) | <0.0001 | 56 | 0.01 |
Polyoma infection | 2 | 975 | Random | 1.05 (0.03-40.89) | 0.98 | 84 | 0.01 |
Hyperlipidemia | 8 | 4233 | Random | 1.72 (1.35-2.20) | <0.0001 | 60 | 0.01 |
Anti-lipid therapy | 8 | 2905 | Random | 1.35 (1.18-1.54) | <0.0001 | 72 | 0.0007 |
Thrombocytopenia | 3 | 1774 | Fixed | 1.97 (1.19-3.35) | 0.008 | 37 | 0.20 |
Leucopenia | 7 | 3594 | Random | 0.43 (0.29-0.64) | <0.0001 | 59 | 0.02 |
Anemia | 6 | 2734 | Random | 1.21 (0.88-1.68) | 0.24 | 81 | <0.0001 |
Proteinuria | 7 | 2861 | Fixed | 1.79 (1.38-2.31) | <0.0001 | 0 | 0.73 |
Impaired wound healing | 6 | 2374 | Fixed | 1.55 (0.97-2.47) | 0.07 | 0 | 0.49 |
Lymphocele | 7 | 3345 | Fixed | 1.80 (1.38-2.34) | <0.0001 | 0 | 0.71 |
Diarrhea | 7 | 3729 | Random | 0.89 (0.64-1.25) | 0.50 | 80 | <0.0001 |
Peripheral edema | 5 | 2752 | Random | 1.34 (1.08-1.68) | 0.009 | 56 | 0.06 |
Malignancy | 8 | 4250 | Fixed | 0.64 (0.45-0.91) | 0.01 | 32 | 0.17 |
Weighted mean difference | |||||||
Serum creatinine (μmol/L) | 6 | 2427 | Random | 7.79 (−2.18 to 17.76) | 0.13 | 51 | 0.07 |
Creatinine Clearance (mL/min)b | 6 | 2177 | Fixed | −2.41 (−4.55 to −0.26) | 0.03 | 5 | 0.38 |
Total cholesterol (mg/dL) | 6 | 1932 | Random | 33.02 (1.11 to 64.93) | 0.04 | 98 | <0.00001 |
Total triglyceride (mg/dL) | 6 | 1932 | Random | 36.15 (23.65 to 48.64) | <0.00001 | 45 | 0.11 |